

#### IV. 研究成果の刊行に関する一覧表



## 研究成果の刊行に関する一覧表

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akizuki S., Ishigaki K., Kochi Y., Law S. M., Matsuo K., Ohmura K., Suzuki A., Nakayama M., Iizuka Y., Koseki H., Ohara O., Hirata J., Kamatani Y., Matsuda F., Sumida T., Yamamoto K., Okada Y., Mimori T. and Terao C.	PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes	<i>Ann Rheum Dis</i>	78(4)	509-518	2019
Kohsaka H., Mimori T., Kanda T., Shimizu J., Sunada Y., Fujimoto M., Kawaguchi Y., Jinnin M., Muro Y., Ishihara S., Tomimitsu H., Ohta A. and Sumida T.	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists	<i>J Dermatol</i>	46(1)	e1-e18	2019
Kohsaka H., Mimori T., Kanda T., Shimizu J., Sunada Y., Fujimoto M., Kawaguchi Y., Jinnin M., Muro Y., Ishihara S., Tomimitsu H., Ohta A. and Sumida T.	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists	<i>Mod Rheumatol</i>	29(1)	1-19	2019
Segawa S., Kondo Y., Nakai Y., Iizuka A., Kaneko S., Yokosawa M., Furuyama K., Tsuboi H., Goto D., Matsumoto I. and Sumida T.	Placenta Specific 8 Suppresses IL-18 Production through Regulation of Autophagy and Is Associated with Adult Still Disease	<i>J Immunol</i>	201(12)	3534-3545	2018
Mimura T., Kondo Y., Ohta A., Iwamoto M., Ota A., Okamoto N., Kawaguchi Y., Kono H., Takasaki Y., Takei S., Nishimoto N., Fujimoto M., Asanuma Y. F., Mimori A., Okiyama N., Kaneko S., Takahashi H., Yokosawa M. and Sumida T.	Evidence-based clinical practice guideline for adult Still's disease	<i>Mod Rheumatol</i>	28(5)	736-757	2018

<p>Kochi Y., Kamatani Y., Kondo Y., Suzuki A., Kawakami E., Hiwa R., Momozawa Y., <u>Fujimoto M.</u>, <u>Jinnin M.</u>, <u>Tanaka Y.</u>, <u>Kanda T.</u>, Cooper R. G., Chinoy H., Rothwell S., Lamb J. A., Vencovsky J., Mann H., Ohmura K., Myouzen K., Ishigaki K., <u>Nakashima R.</u>, Hosono Y., Tsuboi H., Kawasumi H., Iwasaki Y., Kajiyama H., Horita T., Ogawa-Momohara M., Takamura A., Tsunoda S., Shimizu J., <u>Fujio K.</u>, <u>Amano H.</u>, Mimori A., <u>Kawakami A.</u>, Umehara H., <u>Takeuchi T.</u>, Sano H., <u>Muro Y.</u>, <u>Atsumi T.</u>, <u>Mimura T.</u>, <u>Kawaguchi Y.</u>, Mimori T., Takahashi A., Kubo M., Kohsaka H., <u>Sumida T.</u> and Yamamoto K.</p>	<p>Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis</p>	<p><i>Ann Rheum Dis</i></p>	<p>77(4)</p>	<p>602-611</p>	<p>2018</p>
<p>Kondo Y., Yokosawa M., Kaneko S., Furuyama K., Segawa S., Tsuboi H., Matsumoto I. and <u>Sumida T.</u></p>	<p>Transcriptional Regulation of CD4+ T Cell Differentiation in Experimentally Induced Arthritis and Rheumatoid Arthritis</p>	<p><i>Arthritis Rheumatol</i></p>	<p>70(5)</p>	<p>653-661</p>	<p>2018</p>
<p>Oku K., <u>Atsumi T.</u>, Akiyama Y., <u>Amano H.</u>, Azuma N., Bohgaki T., Asanuma Y. F., Horita T., Hosoya T., Ichinose K., Kato M., Katsumata Y., <u>Kawaguchi Y.</u>, <u>Kawakami A.</u>, Koga T., Kohsaka H., Kondo Y., Kubo K., <u>Kuwana M.</u>, Mimori A., Mimori T., <u>Mimura T.</u>, Murakami K., Nakano K., Nakayamada S., Ogishima H., Ohmura K., Saito K., Sano H., Shibuya M., Takahashi Y., Takasaki Y., <u>Takeuchi T.</u>, Tamura N., <u>Tanaka Y.</u>, Tsuboi H., Tsunoda S., Yukawa N., Yamakawa N., Yamamoto K. and <u>Sumida T.</u></p>	<p>Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC)</p>	<p><i>Mod Rheumatol</i></p>	<p>28(4)</p>	<p>642-648</p>	<p>2018</p>

Sumida T., Azuma N., Moriyama M., Takahashi H., Asashima H., Honda F., Abe S., Ono Y., Hirota T., Hirata S., <u>Tanaka Y.</u> , Shimizu T., Nakamura H., <u>Kawakami A.</u> , Sano H., Ogawa Y., <u>Tsubota K.</u> , Ryo K., Saito I., Tanaka A., <u>Nakamura S.</u> , <u>Takamura E.</u> , Tanaka M., Suzuki K., <u>Takeuchi T.</u> , Yamakawa N., Mimori T., <u>Ohta A.</u> , Nishiyama S., Yoshihara T., Suzuki Y., Kawano M., <u>Tomiita M.</u> and Tsuboi H.	Clinical practice guideline for Sjogren's syndrome 2017	<i>Mod Rheumatol</i>	28(3)	383-408	2018
Yamagata K., Usui J., Nagata M., Sugiyama H., Sada K. E., Muso E., Harigai M., Amano K., <u>Atsumi T.</u> , Fujimoto S., <u>Yuzawa Y.</u> , Kobayashi M., Saito T., Ito T., Hirawa N., Homma S., Dobashi H., Tsuboi N., Ishizu A., Arimura Y., Makino H., Matsuo S., Research Committee of Intractable Renal D., the Research Committee of Intractable Vasculitis Syndrome of the Ministry of Health L. and Welfare of J.(Fujii T)	Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study	<i>Clin Exp Nephrol</i>	23(3)	387-394	2019
Ohnishi N, Fujieda Y, Hisada R, Nakamura H, Kato M, Oku K, Amengual O, Yasuda S, <u>Atsumi T.</u>	Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome.	<i>Rheumatology (Oxford)</i>			in press
Fujieda Y., Amengual O. and <u>Atsumi T.</u>	Pathogenic role of antiphospholipid antibodies: an update	<i>Lupus</i>	27(13)	2012-2013	2018
Kato M, Hisada R, Atsumi T.	Clinical profiles and risk assessment in patients with antiphospholipid antibodies.	<i>Expert Rev Clin Immunol.</i>			in press
Abe N, Oku K, Amengual O, Fujieda Y, Kato M, Bohgaki T, Yasuda S, Mori R, Morishita E, Suzuki-Inoue K, <u>Atsumi T.</u>	Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: a systematic review and meta-analysis.	<i>ModRheumatol</i>	17	1-21	
Kanda M. and <u>Atsumi T.</u>	Thrombopoietin mimetics for systemic lupus erythematosus with antiphospholipid antibodies should be discussed separately	<i>Lupus</i>	27(11)	1876-1877	2018

Terao C., Yoshifuji H., Matsumura T., Naruse T. K., <u>Ishii T.</u> , Nakaoka Y., Kirino Y., Matsuo K., Origuchi T., Shimizu M., Maejima Y., Amiya E., Tamura N., Kawaguchi T., Takahashi M., Setoh K., Ohmura K., Watanabe R., Horita T., <u>Atsumi T.</u> , Matsukura M., Miyata T., Kochi Y., Suda T., Tanemoto K., Meguro A., Okada Y., Ogimoto A., Yamamoto M., Takahashi H., Nakayamada S., Saito K., <u>Kuwana M.</u> , Mizuki N., Tabara Y., Ueda A., Komuro I., Kimura A., Isobe M., Mimori T. and Matsuda F.	Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis	<i>Proc Natl Acad Sci U S A</i>	115(51)	13045-13050	2018
Oku K, <u>Atsumi T.</u>	Systemic lupus erythematosus; nothing stale her infinite variety.	<i>ModRheumatol</i>	28(5)	758-765	
Hisada R, Kato M, Ohnishi N, Sugawara E, Fujieda Y, Oku K, Bohgaki T, Amengual O, Yasuda S, <u>Atsumi T.</u>	Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus.	<i>Rheumatology (Oxford)</i>			in press
Kaneko Y., <u>Kameda H.</u> , Ikeda K., <u>Ishii T.</u> , Murakami K., Takamatsu H., <u>Tanaka Y.</u> , Abe T. and <u>Takeuchi T.</u>	Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial	<i>Ann Rheum Dis</i>	77(12)	1720-1729	2018
Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, Ito H, Kuwana M, Matsubara H, Momomura SI, Nishimura M, Ogino H, Satoh T, Shimokawa H, Yamauchi-Takahara K, Tatsumi K, Ishibashi-Ueda H, Yamada N, Yoshida S, Abe K, Ogawa A, Ogo T, Kasai T, Kataoka M, Kawakami T, Kogaki S, Nakamura M, Nakayama T, Nishizaki M, Sugimura K, Tanabe N, Tsujino I, Yao A, Akasaka T, Ando M, Kimura T, Kuriyama T, Nakanishi N, Nakanishi T, Tsutsui H	Japanese Circulation Society and the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group. Guidelines for the Treatment of Pulmonary Hypertension	<i>Circ J</i>			in press

Yasuoka H, Shirai Y, Tamura Y, <u>Takeuchi T</u> , <u>Kuwana M</u> .	Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.	<i>Circ J</i>	82	546-554	2018
Ueki M, <u>Kobayashi I</u> , Takezaki S, et.al.	Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.	<i>Mod Rheumatol</i>	29	351-356,	2019
Concha JSS, Patsatsi A, Marshak-Rothstein A, Liu ML, Sinha AA, Lee LA, Merola JF, Jabbari A, Gudjonsson JE, Chasset F, Jarrett P, Chong B, Arkin L, Fernandez AP, Caproni M, Greenberg SA, Kim HJ, Pearson DR, Femia A, Vleugels RA, Fiorentino D, <u>Fujimoto M</u> , Wenzel J, Werth VP.	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations.	<i>J Invest Dermatol.</i>	139(2)	270-276	2019
Nakamura N, Izumi R, Hoshi Y, Takai Y, Ono R, Suzuki N, Nagai T, Ishii Y, Ishii T, Harigae H, Okada S, Aiba S, Okiyama N, <u>Fujimoto M</u> , Kuroda H, Tateyama M, Aoki M.	FDG-PET detects extensive calcinosis cutis in anti-NXP2 antibody-positive dermatomyositis.	<i>Rheumatology (Oxford). online</i>			2019
Okiyama N, Inoue S, Saito A, Nakamura Y, Ishitsuka Y, Fujisawa Y, Watanabe R, <u>Fujimoto M</u> .	Antihelix/helix violaceous macules in Japanese patients with anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis.	<i>Br J Dermatol. online</i>			2018
Ueda-Hayakawa I, Hamaguchi Y, Okiyama N, Motegi S, Yamaoka T, Miyake S, Higashi A, Okamoto H, Takehara K, <u>Fujimoto M</u>	Autoantibody to transcriptional intermediary factor-1 $\beta$ as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.	<i>M. Br J Dermatol online.</i>			2018
Inoue S, Okiyama N, Shobo M, Motegi S, Hirano H, Nakagawa Y, Saito A, Nakamura Y, Ishitsuka Y, Fujisawa Y, Watanabe R, <u>Fujimoto M</u> .	Diffuse erythema with 'angel wings' sign in Japanese patients with anti-small ubiquitin-like modifier activating enzyme antibody-associated dermatomyositis.	<i>Br J Dermatol.</i>	179(6)	1414-1415.,	2018

Nawata T, Kubo M, Oishi K, Murata Y, Oishi M, Okazaki Y, Omoto M, <u>Kanda T</u> , <u>Kuwana M</u> , and Yano M	A case of cancer-associated myositis with anti-Mi-2 antibodies: false-positive anti-transcriptional intermediary factor 1-g antibodies by commercial enzyme-linked immunosorbent assay	<i>Int. J. Rheum. Dis</i>				Epub ahead of print
Shima Y., <u>Kawaguchi Y.</u> and <u>Kuwana M.</u>	Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy	<i>Mod Rheumatol</i>	29(1)	134-139	2019	
Sato S., Masui K., Nishina N., <u>Kawaguchi Y.</u> , <u>Kawakami A.</u> , Tamura M., Ikeda K., Nunokawa T., Tanino Y., Asakawa K., Kaneko Y., Gono T., Ukichi T., Kaieda S., Naniwa T., <u>Kuwana M.</u> and investigators J.	Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients)	<i>Rheumatology (Oxford)</i>			2018	
Shimura K., Miura J., Kawamoto M., <u>Kawaguchi Y.</u> , Yamanaka H. and Uchigata Y.	Genetic differences between type 1 diabetes with and without other autoimmune diseases	<i>Diabetes Metab Res Rev</i>	34(7)	e3023	2018	
Kawasumi H., Katsumata Y., Nishino A., Hirahara S., <u>Kawaguchi Y.</u> , <u>Kuwana M.</u> and Yamanaka H.	Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases	<i>J Rheumatol</i>	45(7)	947-955	2018	
Ichimura Y., <u>Kawaguchi Y.</u> , Takagi K., Tochimoto A., Higuchi T., Kataoka S., Katsumata Y. and Yamanaka H.	Capillary abnormalities observed by nailfold video-capillaroscopy in Japanese patients with systemic sclerosis	<i>Mod Rheumatol</i>	28(6)	1066-1068	2018	
Kirino Y., <u>Kawaguchi Y.</u> , Tada Y., Tsukamoto H., Ota T., Iwamoto M., Takahashi H., Nagasawa K., <u>Takei S.</u> , Horiuchi T., Ichida H., Minota S., Ueda A., <u>Ohta A.</u> and Ishigatsubo Y.	Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still's disease: A multicenter retrospective study	<i>Mod Rheumatol</i>	28(5)	858-864	2018	



Nakatsuka Y., Handa T., <u>Nakashima R.</u> , Tanizawa K., Kubo T., Murase Y., Sokai A., Ikezoe K., Hosono Y., Watanabe K., Tokuda S., Uno K., Yoshizawa A., Tsuruyama T., Uozumi R., Nagai S., Hatta K., Taguchi Y., Mishima M., Chin K., Mimori T. and Hirai T.	Serum matrix metalloproteinase levels in polymyositis/dermatomyositis patients with interstitial lung disease)	<b><i>Rheumatology (Oxford)</i></b>				2019
Nishioka A., Tsunoda S., Abe T., Yoshikawa T., Takata M., Kitano M., Matsui K., <u>Nakashima R.</u> , Hosono Y., Ohmura K., Mimori T. and Sano H.	Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis)	<b><i>Mod Rheumatol</i></b>		1-7		2018
Hozumi H, Fujisawa T, <u>Nakashima R.</u> , Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Enomoto N, Inui N, Nakamura Y, Mimori T, Suda T.	Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.	<b><i>J Rheumatol.</i></b>	e-Pub a head of print			2019
Shirai T., Shirota Y., Fujii H., <u>Ishii T.</u> and Harigae H.	Four distinct clinical phenotypes of vasculitis affecting medium-sized arteries)	<b><i>Scand J Rheumatol</i></b>		1-7		2019
Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N.	Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).	<b><i>Ann Rheum Dis.</i></b>	77(3)	348-354		2018
Ishii Y., Shirai T., Hoshi Y., Fujita Y., Shirota Y., Fujii H., <u>Ishii T.</u> and Harigae H.	Nasal Septal Perforation in Propylthiouracil-Induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	<b><i>Case Rep Rheumatol</i></b>	2018	8192021		2018
Shirai T., Hanaoka R., Goto Y., Kojima I., Ishii Y., Hoshi Y., Fujita Y., Shirota Y., Fujii H., <u>Ishii T.</u> and Harigae H.	Takayasu Arteritis Coexisting with Sclerosing Osteomyelitis	<b><i>Intern Med</i></b>	57(13)	1929-1934		2018
Shirai T., Fujii H., Saito R., Nasu K., Kamogawa Y., Fukuhara N., Fujita Y., Shirota Y., <u>Ishii T.</u> and Harigae H.	Relapsing Polychondritis Complicated by Myelodysplastic Syndrome Is Resistant to Immunosuppression: Comment on the Article by Dion et al	<b><i>Arthritis Rheumatol</i></b>	69(3)	682-683		2017

Ohtsuji M., Lin Q., Okazaki H., Takahashi K., <u>Amano H.</u> , Yagita H., Nishimura H. and Hirose S.	Anti-CD11b antibody treatment suppresses the osteoclast generation, inflammatory cell infiltration, and autoantibody production in arthritis-prone FcgammaRIIB-deficient mice	<i>Arthritis Res Ther</i>	20(1)	25	2018
Lin Q., Ohtsuji M., <u>Amano H.</u> , Tsurui H., Tada N., Sato R., Fukuyama H., Nishimura H., Verbeek J. S. and Hirose S.	FcgammaRIIb on B Cells and Myeloid Cells Modulates B Cell Activation and Autoantibody Responses via Different but Synergistic Pathways in Lupus-Prone Yaa Mice	<i>J Immunol</i>	201(11)	3199-3210	2018
Miyashita T, Morimoto S, Honda D, Nakano S, <u>Amano H.</u> , Osawa I, Yamaji K, Tomino Y, Takasaki Y, Tamura N.	Outcomes of the Re-classification of WHO Class IV Lupus Nephritis Using the ISN/RPS Classification: a Single Center Retrospective Observational Study from the JUDE Study.	<i>Juntendo Med J</i>	63(5)	362-9	2017
Minowa K, <u>Amano H.</u> , Ando S, Watanabe T, Ogasawara M, Kawano S, Kaneko T, Morimoto S, Yamaji K, Tamura N, Tokano Y, Hashimoto H, Takasaki Y.	Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study.	<i>Mod Rheumatol</i>	27(1)	72-6	2017
Tsukamoto M., Suzuki K. and <u>Takeuchi T.</u>	Initial presentation determines clinical entity in patients with anti-centromere antibody positivity	<i>Int J Rheum Dis</i>	22(1)	103-107	2019
Tsukamoto M., Suzuki K. and <u>Takeuchi T.</u>	Ten-year observation of patients with primary Sjogren's syndrome: Initial presenting characteristics and the associated outcomes	<i>Int J Rheum Dis</i>	22(5)	929-933	2019
Yasuoka H., Shirai Y., Tamura Y., <u>Takeuchi T.</u> and <u>Kuwana M.</u>	Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease	<i>Circ J</i>	82(2)	546-554	2018
Ishioka-Takei E., Yoshimoto K., Suzuki K., Nishikawa A., Yasuoka H., Yamaoka K. and <u>Takeuchi T.</u>	Increased proportion of a CD38(high)IgD(+) B cell subset in peripheral blood is associated with clinical and immunological features in patients with primary Sjogren's syndrome	<i>Clin Immunol</i>	187	85-91	2018

Tsukamoto M., Suzuki K. and <u>Takeuchi T.</u>	Clinical and Immunological Features of Anti-centromere Antibody-Positive Primary Sjogren's Syndrome	<b><i>Rheumatol Ther</i></b>	5(2)	499-505	2018
Inoue Y, Mitsunaga K, Yamamoto T, Chiba K, Yamaide F, Nakano T, Yamaide A, Suzuki S, Arima T, Yamaguchi KI, <u>Tomiita M.</u> , Shimojo N, Kohno Y.	Early use of alendronate as a prospective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study.	<b><i>Pediatric Rheumatol Online J</i></b>	16(1)	36-44	2018
Sonobe H., Ogawa Y., Yamada K., Shimizu E., Uchino Y., Kamoi M., Saijo Y., Yamane M., Citterio D., Suzuki K. and Tsubota K.	A novel and innovative paper-based analytical device for assessing tear lactoferrin of dry eye patients	<b><i>Ocul Surf</i></b>	17(1)	160-166	2019
Ogawa Y, Shimizu E, <u>Tsubota K.</u>	Special Issue; Mechanisms of Disease in Sjögren Syndrome. Interferons and dry eye in Sjögren's syndrome.	<b><i>Int J Mol Sci</i></b>	19	3548	2018
<u>Tsubota K.</u>	Dry Eye Research Update in Japan in Celebration of the 25th Anniversary of the Dry Eye Society and the 10th Anniversary of Hakone Dry Eye Club	<b><i>Invest Ophthalmol Vis Sci</i></b>	59(11)	DESi-DE Sii	2018
Kurose N., Futatsuya C., Mizutani K. I., Kumagai M., Shioya A., Guo X., Aikawa A., Nakada S., Fujimoto S., Kawabata H., <u>Masaki Y.</u> , Takai K., Aoki S., Kojima M., <u>Nakamura S.</u> and Yamada S.	The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome	<b><i>Hum Pathol</i></b>	77	130-138	2018
Sakamoto M., Moriyama M., Shimizu M., Chinju A., Mochizuki K., Munemura R., Ohya K., Maehara T., Ogata K., Ohta M., Yamauchi M., Ishiguro N., Matsumura M., Ohya Y., Kiyoshima T. and <u>Nakamura S.</u>	The diagnostic utility of submandibular gland sonography and labial salivary gland biopsy in IgG4-related dacryoadenitis and sialadenitis: Its potential application to the diagnostic criteria)	<b><i>Mod Rheumatol</i></b>		1-6	2019
Furusho K, Shibata T, Sato R, Fukui R, Motoi Y, Zhang Y, Saitoh S, Ichinohe T, Moriyama M, <u>Nakamura S.</u> , Miyake K.	Cytidine deaminase enables Toll-like receptor 8 activation by cytidine or its analogs	<b><i>Int Immunol</i></b>	31(3)	167-73	2018

Fujimoto S., Koga T., <u>Kawakami A.</u> , Kawabata H., Okamoto S., Mizuki M., Yano S., Ide M., Uno K., Yagi K., Kojima T., Mizutani M., Tokumine Y., Nishimoto N., Fujiwara H., Nakatsuka S. I., Shiozawa K., Iwaki N., <u>Masaki Y.</u> and Yoshizaki K.	Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan	<i>Mod Rheumatol</i>	28(1)	161-167	2018
Ichinose K., Kitamura M., Sato S., Fujikawa K., Horai Y., Matsuoka N., Tsuboi M., Nonaka F., Shimizu T., Fukui S., Umeda M., Koga T., Kawashiri S. Y., Iwamoto N., Igawa T., Tamai M., Nakamura H., Origuchi T., Nishino T. and <u>Kawakami A.</u>	Podocyte foot process width is a prediction marker for complete renal response at 6 and 12 months after induction therapy in lupus nephritis	<i>Clin Immunol</i>	197	161-168	2018
Nakamura H., Horai Y., Shimizu T. and <u>Kawakami A.</u>	Modulation of Apoptosis by Cytotoxic Mediators and Cell-Survival Molecules in Sjogren's Syndrome	<i>Int J Mol Sci</i>	19(8)		2018
Endo Y., Koga T., Ishida M., Fujita Y., Tsuji S., Takatani A., Shimizu T., Sumiyoshi R., Igawa T., Umeda M., Fukui S., Nishino A., Kawashiri S. Y., Iwamoto N., Ichinose K., Tamai M., Nakamura H., Origuchi T., <u>Kuwana M.</u> , Hosono Y., Mimori T. and <u>Kawakami A.</u>	Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report	<i>Medicine (Baltimore)</i>	97(26)	e11024	2018
Endo Y., Koga T., Suzuki T., Hara K., Ishida M., Fujita Y., Tsuji S., Takatani A., Shimizu T., Sumiyoshi R., Igawa T., Umeda M., Fukui S., Nishino A., Kawashiri S. Y., Iwamoto N., Ichinose K., Tamai M., Nakamura H., Origuchi T., <u>Kuwana M.</u> and <u>Kawakami A.</u>	Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report	<i>Medicine (Baltimore)</i>	97(15)	e0436	2018
Shimizu T, Nakamura H, Takatani A, Umeda M, Horai Y, Kurushima S, Michitsuji T, Nakashima Y, <u>Kawakami A.</u>	Activation of Toll-like receptor 7 signaling in labial salivary glands of primary Sjögren's syndrome patients.	<i>Clin Exp Immunol</i>	17	[Epub ahead of print]	2018

Ichinose K, Kitamura M, Sato S, Eguchi M, Okamoto M, Endo Y, Tsuji S, Takatani A, Shimizu T, Umeda M, Fukui S, Sumiyoshi R, Koga T, Kawashiri SY, Iwamoto N, Igawa T, Tamai M, Nakamura H, Origuchi T, Nishino T, <u>Kawakami A.</u>	Complete renal response at 12 months after induction therapy is associated with the renal relapse-free rate in lupus nephritis ~ a single center retrospective cohort study.	<b>Lupus</b>	12	96120331 9829827 [Epub ahead of print]	2019
Ichinose K, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, Tsuboi M, Nonaka F, Shimizu T, Fukui S, Umeda M, Koga T, Kawashiri SY, Iwamoto N, Tamai M, Nakamura H, Origuchi T, Nishino T, <u>Kawakami A.</u>	Factors predictive of long-term mortality in lupus nephritis: A multicenter retrospective study of a Japanese cohort.	<b>Lupus</b>	12	96120331 9826690 [Epub ahead of print]	2019
Fujimoto S., Kawabata H., Kurose N., Kawanami-Iwao H., Sakai T., Kawanami T., Fujita Y., Fukushima T. and <u>Masaki Y.</u>	Sjogren's syndrome manifesting as clinicopathological features of TAFRO syndrome: A case report	<b>Medicine (Baltimore)</b>	96(50)	e9220	2017
<u>Hirohata S.</u> , Sakuma Y., Matsueda Y., Arinuma Y. and Yanagida T.	Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus	<b>Clin Exp Rheumatol</b>	36(6)	1003-1007	2018
Matsueda Y., Arinuma Y., Nagai T. and <u>Hirohata S.</u>	Elevation of serum anti-glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus	<b>Lupus Sci Med</b>	5(1)	e000281	2018
Doi K., Nishida O., Shigematsu T., Sadahiro T., Itami N., Iseki K., <u>Yuzawa Y.</u> , Okada H., Koya D., Kiyomoto H., Shibagaki Y., Matsuda K., Kato A., Hayashi T., Ogawa T., Tsukamoto T., Noiri E., Negi S., Kamei K., Kitayama H., Kashihara N., Moriyama T., Terada Y. and Japanese Clinical Practice Guideline for Acute Kidney Injury C.	The Japanese clinical practice guideline for acute kidney injury 2016	<b>Clin Exp Nephrol</b>	22(5)	985-1045	2018
Arai H., Hayashi H., Ogata S., Uto K., Saegusa J., Takahashi K., Koide S., Inaguma D., Hasegawa M. and <u>Yuzawa Y.</u>	Progression of immunoglobulin G4-related disease to systematic lupus erythematosus after gastric cancer surgery: A case report	<b>Medicine (Baltimore)</b>	97(51)	e13545	2018

Kubota T, <u>Takei S</u> , Shimizu M, Yasumura J, Nakagishi Y, Kizawa T, Yashiro M, Wakiguchi H, Yamasaki Y, Kawano Y.	Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis: A multi-institutional study in Japan.	<i>Mod Rheumatol</i>	28(5)	826-831	2018
Kadota H., Gono T., Shirai Y., Okazaki Y., Takeno M. and <u>Kuwana M.</u>	Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review	<i>Curr Rheumatol Rep</i>	21(4)	10	2019
Gono T., Okazaki Y., Murakami A. and <u>Kuwana M.</u>	Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody	<i>Mod Rheumatol</i>	29(1)	140-145	2019
Ueki M., Kobayashi I., Takezaki S., Tozawa Y., Okura Y., Yamada M., <u>Kuwana M.</u> and Ariga T.	Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies	<i>Mod Rheumatol</i>	29(2)	351-356	2019
Aoyama J., Hayashi H., Yajima C., Takoi H., Tanaka T., Kashiwada T., Kokuho N., Terasaki Y., Nishikawa A., Gono T., <u>Kuwana M.</u> , Saito Y., Abe S., Seike M. and Gemma A.	Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations	<i>Respir Med Case Rep</i>	26	193-196	2019
Sakamoto S., Okamoto M., Kaieda S., Fujimoto K., Nagata S., Tominaga M., Nakamura M., Zaizen Y., Nouno T., Koga T., Kawayama T., <u>Kuwana M.</u> , Ida H. and Hoshino T.	Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis	<i>Respir Investig</i>	56(6)	464-472	2018
Sato S, Hirakata M, Asano K, and <u>Kuwana M</u>	Anti-aminoacyl tRNA synthetase antibodies in Japanese patients with interstitial lung disease	<i>Open J. Rheumatol. Autoimmun. Dis</i>	8	34-42	2018
Fukue R, Gono T, Hayashi H, Tarasaki Y, and <u>Kuwana M</u>	Rapidly progressive multiple digital gangrenes and diffuse alveolar damage in a patient with anti-synthetase antibody complicated with gastric cancer	<i>J. Clin. Rheumatol</i>			Epub ahead of print
Ogawa-Momohara M., <u>Muro Y.</u> , Kono M. and Akiyama M.	Prognosis of dysphagia in dermatomyositis	<i>Clin Exp Rheumatol</i>	37(1)	165	2019
Ogawa-Momohara M., <u>Muro Y.</u> , Mitsuma T., Katayama M., Yanaba K., Nara M., Kakeda M., Kono M. and Akiyama M.	Strong correlation between cancer progression and anti-transcription intermediary factor 1gamma antibodies in dermatomyositis patients	<i>Clin Exp Rheumatol</i>	36(6)	990-995	2018
Teraishi M., Nakajima K., Ishimoto T., Yamamoto M., Maeda N., <u>Muro Y.</u> and Sano S.	Anti-transcription intermediary factor 1gamma antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer	<i>Int J Rheum Dis</i>	21(4)	900-902	2018

Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, <u>Muro Y</u> , Sakairi T, Hisada T, Kurabayashi M	Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.	<i>Respir Med.</i>	140	1-5	2018
<u>Kameda H.</u> , Fujii T., Nakajima A., Koike R., Sagawa A., Kanbe K., Tomita T., Harigai M., Suzuki Y. and Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid a.	Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis	<i>Mod Rheumatol</i>	29(1)	31-40	2019
Komai T., Inoue M., Okamura T., Morita K., Iwasaki Y., Sumitomo S., Shoda H., Yamamoto K. and <u>Fujio K.</u>	Transforming Growth Factor-beta and Interleukin-10 Synergistically Regulate Humoral Immunity via Modulating Metabolic Signals	<i>Front Immunol</i>	9	1364	2018
Tsuchida Y., Sumitomo S., Ota M., Tsuchiya H., Nagafuchi Y., Shoda H., <u>Fujio K.</u> , Ishigaki K., Yamaguchi K., Suzuki A., Kochi Y. and Yamamoto K.	Reduction of CD83 Expression on B Cells and the Genetic Basis for Rheumatoid Arthritis: Comment on the Article by Thalayasingam et al	<i>Arthritis Rheumatol</i>	70(10)	1695-1696	2018
Sakurai K., Ishigaki K., Shoda H., Nagafuchi Y., Tsuchida Y., Sumitomo S., Kanda H., Suzuki A., Kochi Y., Yamamoto K. and <u>Fujio K.</u>	HLA-DRB1 Shared Epitope Alleles and Disease Activity Are Correlated with Reduced T Cell Receptor Repertoire Diversity in CD4+ T Cells in Rheumatoid Arthritis	<i>J Rheumatol</i>	45(7)	905-914	2018
Teruya S., Okamura T., Komai T., Inoue M., Iwasaki Y., Sumitomo S., Shoda H., Yamamoto K. and <u>Fujio K.</u>	Egr2-independent, Klf1-mediated induction of PD-L1 in CD4(+) T cells	<i>Sci Rep</i>	8(1)	7021	2018
Kitagawa A., Tsuboi N., Yokoe Y., Katsuno T., Ikeuchi H., Kajiyama H., Endo N., Sawa Y., Suwa J., Sugiyama Y., Hachiya A., <u>Mimura T.</u> , Hiromura K. and Maruyama S.	Urinary levels of the leukocyte surface molecule CD11b associate with glomerular inflammation in lupus nephritis	<i>Kidney Int</i>	95(3)	680-692	2019
Araki Y., Aizaki Y., Sato K., Oda H., Kurokawa R. and <u>Mimura T.</u>	Altered gene expression profiles of histone lysine methyltransferases and demethylases in rheumatoid arthritis synovial fibroblasts	<i>Clin Exp Rheumatol</i>	36(2)	314-316	2018

Hanaoka H., Iida H., Kiyokawa T., Takakuwa Y. and <u>Kawahata K.</u>	Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy	<i>Clin Rheumatol</i>	38(2)	585-590	2019
Takakuwa Y., Hanaoka H., Kiyokawa T., Iida H., Fujimoto H., Yamasaki Y., Yamada H. and <u>Kawahata K.</u>	Low-dose rituximab as induction therapy for ANCA-associated vasculitis	<i>Clin Rheumatol</i>	38(4)	1217-1223	2019
Takakuwa Y., Hanaoka H., Kiyokawa T., Iida H., Ishimori K., Uekusa T., Yamada H. and <u>Kawahata K.</u>	Adult-onset Still's disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse)	<i>Clin Exp Rheumatol</i>			2019
Hanaoka H., Iida H., Kiyokawa T., Takakuwa Y. and <u>Kawahata K.</u>	Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor	<i>Int J Rheum Dis</i>	22(3)	468-472	2019
Hanaoka H., Iida H., Kiyokawa T., Takakuwa Y. and <u>Kawahata K.</u>	Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus	<i>Intern Med</i>	58(9)	1257-1262	2019
Uchida M., Ooka S., Goto Y., Suzuki K., Fujimoto H., Ishimori K., Matsushita H., Takakuwa Y. and <u>Kawahata K.</u>	Anti-IL-10 antibody in systemic lupus erythematosus	<i>Open Access Rheumatol</i>	11	61-65	2019
Asari Y., Yamasaki Y., Tsuchida K., Suzuki K., Akashi Y. J., Okazaki T., Ozaki S., Yamada H. and <u>Kawahata K.</u>	Hemodynamic heterogeneity of connective tissue disease patients with borderline mean pulmonary artery pressure and its distinctive characters from those with normal pulmonary artery pressure: a retrospective study	<i>Clin Rheumatol</i>	37(12)	3373-3380	2018
Hanaoka H., Iida H., Kiyokawa T., Takakuwa Y. and <u>Kawahata K.</u>	A positive direct Coombs' test in the absence of hemolytic anemia predicts high disease activity and poor renal response in systemic lupus erythematosus	<i>Lupus</i>	27(14)	2274-2278	2018
Shimizu J., Yamano Y., <u>Kawahata K.</u> and Suzuki N.	Relapsing polychondritis patients were divided into three subgroups: patients with respiratory involvement (R subgroup), patients with auricular involvement (A subgroup), and overlapping patients with both involvements (O subgroup), and each group had distinctive clinical characteristics	<i>Medicine (Baltimore)</i>	97(42)	e12837	2018



Hanaoka H., Iida H., Kiyokawa T., Takakuwa Y., Okazaki T., Yamada H., Ozaki S. and <u>Kawahata K.</u>	Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome	<i>PLoS One</i>	13(5)	e0196172	2018
Umezawa N., <u>Kawahata K.</u> , Mizoguchi F., Kimura N., Yoshihashi-Nakazato Y., Miyasaka N. and Kohsaka H.	Interleukin-23 as a therapeutic target for inflammatory myopathy	<i>Sci Rep</i>	8(1)	5498	2018
Iida H, Hanaoka H, Okada Y, Kiyokawa T, Takakuwa Y, Yamada H, Okazaki T, Ozaki S, Yamaguchi K, Nakajima Y, <u>Kawahata K.</u>	A low perfusion-metabolic mismatch in 99m Tl and 123 I-BMIPP scintigraphy predicts poor prognosis in systemic sclerosis patients with asymptomatic cardiac involvement.	<i>Int J Rheum Dis</i>		doi: 10.1111/1756-185X.13508	2019
Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, <u>Kawahata K.</u>	Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV.	<i>Arthritis Res Ther</i>	20(1)	86	2018
<u>Shimizu M.</u> , Mizuta M., Yasumi T., Iwata N., Okura Y., Kinjo N., Umabayashi H., Kubota T., Nakagishi Y., Nishimura K., Yashiro M., Yasumura J., Yamazaki K., Wakiguchi H., Okamoto N. and <u>Mori M.</u>	Validation of Classification Criteria of Macrophage Activation Syndrome in Japanese Patients With Systemic Juvenile Idiopathic Arthritis	<i>Arthritis Care Res (Hoboken)</i>	70(9)	1412-1415	2018
Matsui T., Matsumoto T., Hirano F., Tokunaga F., Okamoto K., Tohma S., Morio T., Kohsaka H. and <u>Mori M.</u>	Survey of the awareness of adult rheumatologists regarding transitional care for patients with juvenile idiopathic arthritis in Japan	<i>Mod Rheumatol</i>	28(6)	981-985	2018
<u>Mori M.</u> , Hara T., Kikuchi M., Shimizu H., Miyamoto T., Iwashima S., Oonishi T., Hashimoto K., Kobayashi N., Waki K., Suzuki Y., Otsubo Y., Yamada H., Ishikawa C., Kato T. and Fuse S.	Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial	<i>Sci Rep</i>	8(1)	1994	2018
<u>Mori M.</u> , Nakagawa M., Tsuchida N., Kawada K., Sato J., Sakiyama M., Hirano S., Sato K. and Nakamura H.	Proposal for the development of biologics in pediatric rheumatology	<i>Pediatr Int</i>	60(2)	108-114	2018

<u>Mori M.</u> , Sugiyama N., Morishima Y., Sugiyama N., Kokubo T., Takei S. and Yokota S.	Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance	<i>Mod Rheumatol</i>	28(1)	101-107	2018
Nakaseko H., Iwata N., Yasuoka R., Kohagura T., Abe N., Kawabe S. and <u>Mori M.</u>	Pharmacokinetics of mycophenolate mofetil in juvenile patients with autoimmune diseases)	<i>Mod Rheumatol</i>	1-15		2018
Sakurai N., Hino-Shishikura A., Nozawa T., Kamide H., Ohara A., Nishimura K., Kikuchi M., Hara R., <u>Mori M.</u> and Ito S.	Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis)	<i>Mod Rheumatol</i>	1-6		2018
Yokoyama K., <u>Mori M.</u> and Yoshida A.	Mycophenolate mofetil therapy for two cases of antiphospholipid antibody-associated chorea	<i>Mod Rheumatol</i>	28(4)	709-711	2018
Sakumura N., <u>Shimizu M.</u> , Mizuta M, Inoue N, Nakagishi Y, Yachie A.	Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis.	<i>Cytokine</i>	110	459-65	2018
<u>Okamoto N.</u> , Yokota S., <u>Takei S.</u> , Okura Y., Kubota T., <u>Shimizu M.</u> , Nozawa T., Iwata N., Umebayashi H., Kinjo N., Kunishima T., Yasumura J. and <u>Mori M.</u>	Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018	<i>Mod Rheumatol</i>	29(1)	41-59	2019
Takakura M., <u>Shimizu M.</u> , Yakoyama T., Mizuta M. and Yachie A.	Transient natural killer cell dysfunction associated with interleukin-18 overproduction in systemic juvenile idiopathic arthritis	<i>Pediatr Int</i>	60(10)	984-985	2018
Shabana K., <u>Okamoto N.</u> , Sugita Y., Shindo K., Murata T., Tamai H. and Fujiwara K.	The findings of musculoskeletal ultrasonography on primary Sjogren's syndrome patients in childhood with articular manifestations and the impact of anti-cyclic citrullinated peptide antibody)	<i>Mod Rheumatol</i>		1-20	2018
Kumagai H., Tobina T., Ichinoseki-Sekine N., Kakigi R., Tsuzuki T., Zempo H., Shiose K., Yoshimura E., Kumahara H., Ayabe M., Higaki Y., <u>Yamada R.</u> , Kobayashi H., Kiyonaga A., Naito H., Tanaka H. and Fuku N.	Role of selected polymorphisms in determining muscle fiber composition in Japanese men and women	<i>J Appl Physiol (1985)</i>	124(5)	1377-1384	2018

Wang J. and Yamada R.	In silico study of medical decision-making for rare diseases: heterogeneity of decision-makers in a population improves overall benefit	<i>PeerJ</i>	6	e5677	2018
富板美奈子	小児期のシェーグレン症候群の診断と外来フォローのポイント	小児科	60(3)	251-257	2019
富板美奈子	小児期シェーグレン症候群	日本臨牀	77(3)	484-488	2019
五野貴久、桑名正隆	成人特発性炎症性筋疾患	日本臨牀	77(3)	456-461	2019
桑名正隆	炎症性筋疾患と自己抗体	Medical Practice	35(6)	879-884	2018
藤井 隆夫、野澤 和久、高崎 芳成	小型血管炎. ANCA 関連血管炎 ; 専門領域の視点から. 診療科による ANCA 関連血管炎治療に対する考え方の相違について	日本臨床	76	371-376	2018
小林一郎	Single Hub and Access point for pediatric Rheumatology in Europe (SHARE)による若年性皮膚筋炎における推奨,	リウマチ科	59	381	2018

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
坪井洋人、萩原晋也、 <u>住田孝之</u>	病型と診断基準、分類基準	竹内勤、川上純、住田孝之	シェーグレン症候群の診断と治療マニュアル	診断と治療社	東京	2018	2-13
<u>住田孝之</u>	これからの治療と展望	竹内勤、川上純、住田孝之	シェーグレン症候群の診断と治療マニュアル	診断と治療社	東京	2018	225-230
鬼澤 秀夫、 <u>中嶋 蘭</u>	医学用語解説 MDA5	宮坂 信之	炎症と免疫	先端医学社	東京都	2018	548-551
<u>正木康史</u>	第4章 臨床症状 2 腺外症状 1) 血液リンパ増殖性病変 第4章 臨床症状 5 IgG4 関連疾患 1) 診断	日本シェーグレン症候群学会	シェーグレン症候群の診断と治療マニュアル 改訂第3版	診断と治療社	東京	2018	p117-122, p178-186
<u>正木康史</u>	第2部 各疾患別ステロイドの使い方 正木康史 2. 血液疾患	山本一彦	改訂第3版ステロイドの選び方・使い方ハンドブック	羊土社	東京	2018	p113-139
森山 雅文、 <u>中村 誠司</u>	第3章 診断手技・手法 1. 唾液分泌量の測定	日本シェーグレン症候群学会	シェーグレン症候群の診断と治療マニュアル 改訂第3版	診断と治療社	東京	2018	44-47
森山 雅文、 <u>中村 誠司</u>	第5章 対応と治療 2. 口腔乾燥症の対応と治療	日本シェーグレン症候群学会	シェーグレン症候群の診断と治療マニュアル 改訂第3版	診断と治療社	東京	2018	214-218
小川葉子、 <u>坪田一男</u>	涙腺生検病理診断.	日本シェーグレン症候群学会編集 竹内勤、川上 純、住田孝之 監修.	シェーグレン症候群の診断と治療マニュアル. 改訂第3版	診断と治療社	東京	2018	76-82
<u>高村悦子</u>	Schirmer テスト・涙液層破壊時間・角結膜染色検査	日本シェーグレン症候群学会編集、竹内勤、川上純、住田孝之監修	シェーグレン症候群の診断と治療マニュアル改訂第3版	診断と治療社	東京	2018	
<u>富板美奈子</u>	小児のシェーグレン症候群	日本シェーグレン症候群学会	シェーグレン症候群の診断と治療マニュアル改訂第3版	診断と治療社	東京	2018	168-177

富板美奈子	小児期シェーグレン症候群診断の手引き	厚生労働科学研究費補助金難治性疾患等政策研究事業若年性特発性関節炎と主とした小児リウマチ性疾患の診断基準・重症度分類の標準化とエビデンスに基づいたガイドラインの策定に関する研究班シェーグレン症候群分担任	小児期シェーグレン症候群診療の手引き	羊土社	東京	2018	31-36
富板美奈子	Sjögren 症候群	「小児内科」・「小児外科」合同編集委員会	小児疾患の診断・治療基準 小児内科 50 巻臨時増刊号	東京医学社	東京	2018	306-307
富板美奈子	IGG4 関連疾患	稲毛康司	小児科ステロイドの使い方・止め方・続け方	文光堂	東京	2019	88-91
秋葉靖、富板美奈子	エリテマトーゼス	大嶋勇成、宮地良樹	こどもの皮膚の診かた	診断と治療社	東京	2019	157-159
Hirohata S.	Epidemiology of Neuropsychiatric Systemic Lupus Erythematosus	Hirohata S.	Neuropsychiatric Systemic Lupus Erythematosus: Pathogenesis, Clinical Aspects and Treatment.	Springer International Publishing AG	New York, NY	2018	pp. 1-14
Hirohata S.	Immunopathology of Neuropsychiatric Systemic Lupus Erythematosus	Hirohata S.	Neuropsychiatric Systemic Lupus Erythematosus: Pathogenesis, Clinical Aspects and Treatment.	Springer International Publishing AG	New York, NY	2018	pp. 29-42
Hirohata S.	Pathology of Neuropsychiatric Systemic Lupus Erythematosus	Hirohata S.	Neuropsychiatric Systemic Lupus Erythematosus: Pathogenesis, Clinical Aspects and Treatment.	Springer International Publishing AG	New York, NY	2018	pp. 43-58

Arinuma Y, <u>Hirohata S.</u>	Clinical Features	<u>Hirohata S.</u>	Neuropsychiatric Systemic Lupus Erythematosus: Pathogenesis, Clinical Aspects and Treatment.	pringer International Publishing AG	New York, NY	2018	pp. 59-76
Arinuma Y, <u>Hirohata S.</u>	Imaging of Neuropsychiatric Systemic Lupus Erythematosus	<u>Hirohata S.</u>	Neuropsychiatric Systemic Lupus Erythematosus: Pathogenesis, Clinical Aspects and Treatment.	pringer International Publishing AG	New York, NY	2018	pp. 123-128
厚労科研:JIAを主とした小児リウマチ性疾患の診断基準・重症度分類の標準化とエビデンスに基づいたガイドラインの策定に関する研究班（代表、森雅亮）	小児 SLE 診療の手引き 2018	武井修治	小児 SLE の診療の手引き 2018	羊土社	東京	2018	
<u>亀田秀人</u>	全身性エリテマトーデス	福井次矢、高木誠、小室一成	今日の治療指針	医学書院	東京	2018	840-842
<u>亀田秀人</u>	ステロイド等価換算、薬物相互作用	山本一彦	ステロイドの選び方・使い方ハンドブック改訂第3版	羊土社	東京	2018	27-33
Araki Y, <u>Mimura T</u>	Chapter 12: Epigenetic Basis of Autoimmune Disorders in Humans.	Trygve Tollefsbol	Epigenetics in Human Disease, 2nd edition.	Elsevier		2018. 5. 18	353-386
<u>三村俊英</u>	X 膠原病・類縁疾患. 9. 成人ステイル病	門脇孝・小室一成・宮地良樹	「診療ガイドライン」UP-TO-DATE2018-2019	メディカルレビュー社		2018. 1. 17	645-649
<u>川畑仁人</u>	リウマチ・膠原病治療総論	川畑仁人	リウマチ・膠原病治療薬ハンドブックーエキスパートが教える極意ー第1版	文光堂	東京	2018	2-6
<u>川畑仁人</u>	添付文書及びガイドラインに基づく薬剤と疾患の対応表	川畑仁人	リウマチ・膠原病治療薬ハンドブックーエキスパートが教える極意ー第1版	文光堂	東京	2018	18-21

川畑仁人	セルトリズマブ ペゴル	川畑仁人	リウマチ・膠原病治療 薬ハンドブックーエ キスパートが教える 極意ー第1版	文光堂	東京	2018	100-106
岡本奈美	分担執筆	厚生労働科学 研究費補助金 難治性疾患等 政策研究事業 自己免疫疾患 に関する調査 研究班	成人スチル病診療ガ イドライン 2017 年版	診断と治療社	東京	2018	
岡本奈美	腺障害の検査	厚生労働科学 研究費補助金 難治性疾患等 政策研究事業 若年性特発性 関節炎を主と した小児リウ マチ性疾患の 診断基準・重 症度分類の標 準化とエビデ ンスに基づい たガイドライ ンの策定に関 する研究班	小児期シェーグレン 症候群診療の手引き 2018 年版	羊土社	東京	2018	27-30
森 雅亮.	若年性特発性関 節炎.		希少疾患用医薬品の 適応拡大と事業性評 価.	技術情報協会	東京	2018	
森 雅亮.	小児リウマチ 性疾患における 薬剤.		リウマチ・膠原病治療 薬ハンドブック.	文光堂	東京	2018	215-231
森 雅亮.	若年性特発性関 節炎.		診断と治療のABC 139 リウマチ・膠原病.	最新医学社	東京	2018	88-97.
岡本奈美	若年性特発性関 節炎 (JIA)	稲毛康司	小児科ステロイドの 使い方・止め方・続け 方.	文光堂	東京	2018	69-71
Kawaguchi S, Higasa K, Yamada R, Matsuda F	Comprehensive HLA typing from a current allele database using next-generation sequencing data	Sebastian Bo megele	HLA Typing	Humana Press, N ew York, NY	New York	2018	225-233